Anti-Malaria Vaccination could be Widely Available by 2016
British pharmaceutical company, GlaxoSmithKline is seeking approval of the world's first anti-malaria vaccination. GSK scientists have reportedly spent nearly three decades developing the vaccine and now hope it will be widely available by 2016.
Malaria is a mosquito-borne disease that kills hundreds of thousands of people worldwide every year. Although most anti-malaria medication is highly effective, scientists say a vaccine is the only way to truly eradicate the disease.
In a trial conducted in Africa, the vaccine, known as ‘RTS,S’ almost halved the number of malaria cases in young children and reduced the number of cases in infants by approximately 25%. It was Africa's largest clinical trial yet, involving almost 15,500 children across seven countries.
“A malaria vaccine has the potential to save hundreds of thousands of lives in the developing world,” said Chetan Chavda of UK-based travel health website, clinidirect.co.uk. “Anti-malaria tablets, mosquito nets and strong insect repellents containing DEET are all effective methods to protect against malaria, but a widely available vaccine could affect people’s lives enormously.”
The trial’s findings were presented at a medical meeting in Durban, South Africa and indicated that 18 months after being vaccinated, children aged 5–17 months had a 46% reduction in the risk of malaria.
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance